Log In
BCIQ
Print this Print this
 

Keppra XR, levetiracetam

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionExtended-release formulation of a high affinity synaptic vesicle protein (SV2A) ligand
Molecular Target Synaptic vesicle protein (SV2A)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationSeizures
Indication DetailsTreat partial onset seizures in patients with epilepsy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$684.1M

$684.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/26/2009

$684.1M

$684.1M

0

Get a free BioCentury trial today